Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galantamine extended release.

Dean M Robinson1, Greg L Plosker

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|July 26, 2006
PubMed
Summary
This summary is machine-generated.

Once-daily galantamine extended release (ER) improved cognitive function in Alzheimer's disease patients, showing similar efficacy to immediate release (IR) galantamine. Both formulations were well-tolerated, with comparable adverse event profiles to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Trials

Background:

  • Galantamine is an acetylcholinesterase inhibitor used for Alzheimer's disease.
  • It increases neurotransmitter concentrations by inhibiting acetylcholine hydrolysis and modulating nicotinic receptors.

Purpose of the Study:

  • To compare the efficacy and safety of once-daily galantamine extended release (ER) 24 mg with twice-daily galantamine immediate release (IR) 12 mg.
  • To evaluate galantamine ER's effect on cognitive performance and global change in Alzheimer's disease patients.

Main Methods:

  • A randomized, double-blind trial comparing galantamine ER and IR to placebo.
  • Bioequivalence assessment of galantamine ER and IR formulations.
  • Evaluation of primary and secondary endpoints, including cognitive performance, global change, and activities of daily living.

Related Experiment Videos

Main Results:

  • Galantamine ER demonstrated significantly greater cognitive improvement than placebo, with efficacy comparable to galantamine IR.
  • No significant effect on global change was observed for galantamine ER or IR in primary analysis.
  • Exploratory analyses suggested nominal significance for galantamine ER on global change.
  • Improvements were noted in activities of daily living and cognitive measures, but not in behavioral measures.

Conclusions:

  • Once-daily galantamine ER is bioequivalent to twice-daily galantamine IR and shows comparable efficacy in improving cognitive performance.
  • Galantamine ER offers a convenient dosing regimen for Alzheimer's disease management.
  • Both galantamine formulations were generally well-tolerated, with similar adverse event rates across groups.